Rekvina Laboratories
30.68
+1.46(+5.00%)
Market Cap₹18.48 Cr
PE Ratio-69.57
IndustryHealthcare
Company Performance:
1D+5.00%
1M-14.78%
6M+57.58%
1Y+333.33%
5Y+707.37%
View Company Insightsright
More news about Rekvina Laboratories
06Apr 26
Rekvina Laboratories Submits Q4FY26 Dematerialisation Compliance Certificate to BSE
Rekvina Laboratories Limited filed its Q4FY26 dematerialisation compliance certificate with BSE on 06.04.2026, covering the period from 1st January, 2026 to 31st March, 2026. The certificate, prepared by registrar M/s. Purva Sharegistry India Pvt. Ltd, shows no dematerialisation activity during the quarter, with 'NIL' entries across all parameters including folio numbers, shareholder names, and certificate numbers. This regulatory filing under SEBI (Depositories and Participants) Regulations, 2018 ensures compliance with quarterly reporting requirements for listed companies.
 no imag found
25Mar 26
Rekvina Laboratories Open Offer: Detailed Public Statement Published for 26% Stake Acquisition
Three acquirers have published a detailed public statement for their mandatory open offer to acquire 28,90,100 equity shares (26% stake) of Rekvina Laboratories at ₹10 per share, following a share swap agreement to acquire Radiant Parenterals. The offer involves ₹2,89,01,000 consideration with escrow arrangements in place and is scheduled to run from May 14-27, 2026.
 no imag found
18Mar 26
Rekvina Laboratories Schedules EGM for April 10 to Approve Capital Restructuring
Rekvina Laboratories has formally notified shareholders of an extraordinary general meeting on April 10, 2026, to vote on increasing authorized share capital from ₹3.50 crore to ₹6 crore, acquiring 100% stake in Radiant Parenterals for ₹4.62 crore through share exchange, and issuing additional equity shares for cash consideration.
 no imag found
17Mar 26
Rekvina Laboratories Discloses Open Offer Public Announcement to BSE
Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers - Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer seeks to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital with total consideration of ₹2,89,01,000. The transaction was triggered by a share exchange agreement for acquiring Radiant Parenterals Limited, managed by Vivro Financial Services under SEBI regulations.
 no imag found
Rekvina Laboratories
30.68
+1.46
(+5.00%)
1 Year Returns:+333.33%
Industry Peers
Sun Pharmaceutical
1,944.40
(-0.03%)
Divis Laboratories
8,300.00
(+0.30%)
Cipla
1,467.70
(+0.27%)
Zydus Life Science
1,119.00
(+0.43%)
Lupin
2,300.00
(-2.69%)
Mankind Pharma
2,438.00
(-0.73%)
Laurus Labs
1,854.00
(+0.53%)
Dr Reddys Laboratories
1,158.80
(-1.13%)
Aurobindo Pharma
1,648.00
(-0.60%)